Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target boosted by stock analysts at Wells Fargo & Company from $150.00 to $165.00 in a note issued to investors on Wednesday, MarketBeat.com reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 8.69% from the company’s previous close.

GILD has been the subject of several other reports. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Daiwa Securities Group raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. Twenty-three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.42.

Gilead Sciences Stock Down 2.6%

Shares of GILD opened at $151.81 on Wednesday. The company has a market capitalization of $188.35 billion, a price-to-earnings ratio of 22.42, a PEG ratio of 0.81 and a beta of 0.36. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The stock’s 50-day moving average price is $129.59 and its 200-day moving average price is $121.98. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the business earned $1.90 earnings per share. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts predict that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider directly owned 103,221 shares in the company, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This represents a 15.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 319,391 shares of company stock worth $44,141,101 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of the business. Csenge Advisory Group increased its holdings in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Railway Pension Investments Ltd grew its holdings in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth $1,274,000. iA Global Asset Management Inc. raised its holdings in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after acquiring an additional 23,046 shares during the period. Finally, Sector Gamma AS raised its holdings in shares of Gilead Sciences by 15.9% during the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after acquiring an additional 20,239 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.